ENGLEWOOD, Colo., Oct. 27, 2020 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a
biopharmaceutical company focused on the advancement of immunology
based therapies for prevalent inflammatory conditions, announced
today it will present at the ROTH Capital Healthcare Event,
"COVID-19 Therapeutics in Development" taking place on
Wednesday, October 28, 2020 –
9:00 AM (ET) / 6:00 AM (PT). This corrects the previous
announcement issued on October 26,
2020, which indicated that Ampio would be presenting at the
2020 MedTech Innovation Forum hosted by ROTH Capital.
The ROTH Healthcare and Biotechnology team are hosting the
webinar to discuss key therapies in development to treat COVID
disease.
The Webinar includes three sessions: "Immune Modulators to
Ameliorate COVID Disease 1," "Direct Antivirals and Other Agents
Against SARS-CoV2 Virus," and "Indirect Antivirals Against
SARS-CoV2 Virus."
To register for the event, please click here.
Forward Looking Statements
Ampio's statements in this
press release that are not historical fact, and that relate to
future plans or events, are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of words
such as "believe," "expect," "plan," "anticipate," and similar
expressions. These forward-looking statements include statements
regarding Ampio's expectations with respect to Ampion and its
classification, as well as those associated with regulatory
approvals and other FDA decisions, the Biological License
Application ("BLA"), the ability of Ampio to enter into
partnering arrangements, clinical trials and decisions and
changes in business conditions and similar events, the ability to
receive regulatory approval to conduct clinical trials, that Ampion
may be used to treat ARDS induced by COVID-19, all of which are
inherently subject to various risks and uncertainties. The risks
and uncertainties involved include those detailed from time to time
in Ampio's filings with the Securities and Exchange Commission,
including without limitation, under Ampio's Annual Report on Form
10-K and other documents filed with the Securities and Exchange
Commission. Ampio undertakes no obligation to revise or update
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Dan
Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com
Ampio Pharmaceuticals, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-present-at-the-roth-capital-healthcare-event-covid-19-therapeutics-in-development-301160562.html
SOURCE Ampio Pharmaceuticals, Inc.